17 July 2026 – Allergan Aesthetics, an AbbVie company, has received European Commission approval for Boey® (trenibotulinumtoxinE), becoming the first and only rapid-onset, short-duration botulinum neurotoxin type E approved in Europe for the temporary improvement of moderate to severe glabellar (frown) lines in adults where the condition has a significant psychological impact.

The approval, granted through the European Union's centralized procedure, allows the product to be marketed across all 30 countries in the European Economic Area (EEA). Boey® also received regulatory approval in Canada in June 2026.

Boey® offers a differentiated treatment option in the facial aesthetics market, with clinical studies demonstrating visible results as early as eight hours after treatment. Unlike conventional botulinum toxin products that can last several months, the effects of Boey® typically wear off within two to three weeks, providing patients with a shorter-duration option.

According to AbbVie, the product was developed to address growing consumer demand for aesthetic treatments that offer greater flexibility and allow individuals to experience the effects of injectable treatments before committing to longer-lasting options.

The company highlighted survey findings indicating increasing interest in facial aesthetic procedures, with many potential patients expressing a desire for treatments that provide a temporary preview of cosmetic results while reducing concerns about long-term commitment.

Boey® was developed by the makers of BOTOX Cosmetic® (marketed as VISTABEL®/Vistabex® in Europe) and expands Allergan Aesthetics' injectable portfolio. The company is preparing for a phased commercial launch across Europe and plans to provide healthcare professionals with education and training to support the product's introduction.

The approval represents a significant addition to the evolving medical aesthetics landscape, offering clinicians and patients a new treatment option with a rapid onset of action and shorter duration compared with existing botulinum toxin therapies.

Source: Allergan Aesthetics (AbbVie)